Kissei Pharmaceutical Co., Ltd. (KSPHF)

OTCMKTS · Delayed Price · Currency is USD
30.28
+3.15 (11.61%)
At close: Aug 6, 2025
11.61%
Market Cap1.21B
Revenue (ttm)619.35M
Net Income (ttm)85.77M
Shares Outn/a
EPS (ttm)1.99
PE Ratio14.12
Forward PEn/a
Dividend0.77 (2.55%)
Ex-Dividend DateSep 29, 2025
Volume100
Average Volume909
Open30.28
Previous Close27.13
Day's Range30.28 - 30.28
52-Week Range23.23 - 30.28
Beta-0.10
RSI70.94
Earnings DateNov 5, 2025

About Kissei Pharmaceutical

Kissei Pharmaceutical Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in Japan. The company offers Kalogra tablets, for the treatment of ulcerative colitis; Tabuneos capsules for the treatment of microscopic polyangiitis and granulomatous polyangiitis; Minirin Melt OD tablets; Malizeb tablets; Tavaris tablets for the treatment of chronic idiopathic thrombocytopenic purpura; Beova tablets for the treatment of overactive bladder treatment; and Darbepoetin Alfa BS injection JCR for the treatment of renal a... [Read more]

Sector Healthcare
Founded 1946
Employees 1,778
Stock Exchange OTCMKTS
Ticker Symbol KSPHF
Full Company Profile

Financial Performance

In 2024, Kissei Pharmaceutical's revenue was 88.33 billion, an increase of 16.87% compared to the previous year's 75.58 billion. Earnings were 11.96 billion, an increase of 7.18%.

Financial numbers in JPY Financial Statements

News

There is no news available yet.